Tom Hughes jumps ship at Zafgen and gets back to the helm of a noteworthy biotech
The battle-tested biotech exec Tom Hughes is headed back to a CEO post.
After leading Zafgen through an IPO, a savage safety crisis and a complete revamp, Hughes stepped down from the CEO role at Zafgen several months ago to take the chief scientific officer’s job as Jeffrey Hatfield was named CEO. Now he’s relocating to another Cambridge/Boston biotech outfit called Navitor, which has just launched its first early-stage clinical study to test the anti-aging theories it’s been working on for the past 4 years.
Basic subscription required
Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.